NASDAQ:COCH Envoy Medical Q4 2024 Earnings Report $0.65 -0.01 (-1.54%) As of 06/23/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Envoy Medical EPS ResultsActual EPS-$0.45Consensus EPS -$0.33Beat/MissMissed by -$0.12One Year Ago EPSN/AEnvoy Medical Revenue ResultsActual Revenue$0.04 millionExpected Revenue$0.07 millionBeat/MissMissed by -$30.00 thousandYoY Revenue GrowthN/AEnvoy Medical Announcement DetailsQuarterQ4 2024Date3/28/2025TimeBefore Market OpensConference Call DateMonday, March 31, 2025Conference Call Time7:00AM ETUpcoming EarningsEnvoy Medical's Q2 2026 earnings is estimated for Thursday, July 30, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Envoy Medical Earnings HeadlinesComparing Envoy Medical (NASDAQ:COCH) and ADB International Group (OTCMKTS:EQUR)June 23 at 2:18 AM | americanbankingnews.comEnvoy Medical (NASDAQ:COCH) Signs Multi-Part Series With New to The StreetJune 4, 2026 | finance.yahoo.comBill Gates said this would never work. Then he wrote a $100M check.Bill Gates spent a decade insisting this energy source couldn't supply more than 5% of global power. Then he toured a construction site in the Nevada desert and told Bloomberg he now believes it could reach 20%. He followed that reversal with a $100 million investment. Facebook's co-founder added $462 million. Tesla's co-founder and Norway's sovereign wealth fund also took positions. One company - 60 years of operating history, revenue approaching $1 billion - sits at the center of all of it, with a July 4th catalyst that locks in its competitive advantage for eight years. | Behind the Markets (Ad)Envoy Medical Granted Extension to Regain Nasdaq ComplianceMay 22, 2026 | tipranks.comEnvoy Medical Inc - Ordinary Shares - Class AMay 15, 2026 | money.usnews.comEnvoy Medical Reaches Critical Milestone in Pivotal Clinical Trial of Fully Implanted Acclaim(R) Cochlear ImplantApril 22, 2026 | finance.yahoo.comSee More Envoy Medical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Envoy Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Envoy Medical and other key companies, straight to your email. Email Address About Envoy MedicalEnvoy Medical (NASDAQ:COCH) (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process. Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals. The company works closely with healthcare providers to integrate its device into patient care pathways, supporting therapy both in clinical environments and at home. Headquartered in the Minneapolis–Saint Paul metropolitan area, Envoy Medical currently serves the U.S. market and is evaluating opportunities for expansion into select international regions. Its leadership team combines expertise in medical device development, rehabilitation sciences and commercial operations, backed by private financing aimed at advancing innovative therapies for neurological and musculoskeletal disorders.View Envoy Medical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Sudden Plunge May Be an AI Buying ChanceLiquid Gold: The AI Cooling Retrofit TradeCopa Holdings May Be the Airline Stock Built to Break OutBuy CrowdStrike Before the Stock Split? Here's the CaseUSA Today's Digital Revival Is Gaining Steam, But With Plenty of RiskBurlington Is Winning Over Shoppers But Investors Need PatienceInvestors Are Buying Into Sweetgreen Again—Should They? Upcoming Earnings Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
